Identification of hub genes and candidate drugs in hepatocellular carcinoma by integrated bioinformatics analysis

Xiaolong Chen, PhD, Zhixiong Xia, PhD, Yafeng Wan, PhD, Ping Huang, PhD*

Abstract

Background: Hepatocellular carcinoma (HCC) is the third cancer-related cause of death in the world. Until now, the involved mechanisms during the development of HCC are largely unknown. This study aims to explore the driven genes and potential drugs in HCC.

Methods: Three mRNA expression datasets were used to analyze the differentially expressed genes (DEGs) in HCC. The bioinformatics approaches include identification of DEGs and hub genes, Gene Ontology terms analysis and Kyoto encyclopedia of genes and genomes enrichment analysis, construction of protein–protein interaction network. The expression levels of hub genes were validated based on The Cancer Genome Atlas, Gene Expression Profiling Interactive Analysis, and the Human Protein Atlas. Moreover, overall survival and disease-free survival analysis of HCC patients were further conducted by Kaplan–Meier plotter and Gene Expression Profiling Interactive Analysis. DGIdb database was performed to search the candidate drugs for HCC.

Results: A total of 197 DEGs were identified. The protein–protein interaction network was constructed using Search Tool for the Retrieval of Interacting Genes software, 10 genes were selected by Cytoscape plugin cytoHubba and served as hub genes. These 10 genes were all closely related to the survival of HCC patients. DGIdb database predicted 29 small molecules as the possible drugs for treating HCC.

Conclusion: Our study provides some new insights into HCC pathogenesis and treatments. The candidate drugs may improve the efficiency of HCC therapy in the future.

Abbreviations: DEG = differentially expressed gene, DFS = disease-free survival, GEO = gene expression omnibus, GEPIA = Gene Expression Profiling Interactive Analysis, GO = Gene Ontology, HCC = hepatocellular carcinoma, HPA = The Human Protein Atlas, KEGG = Kyoto encyclopedia of genes and genomes, LIHC = liver hepatocellular carcinoma, OS = overall survival, PPI = protein–protein interaction, STRING = search tool for the retrieval of interacting genes/proteins, TCGA = The Cancer Genome Atlas.

Keywords: bioinformatics analysis, differently expressed genes, drug, hepatocellular carcinoma, hub genes

1. Introduction

Hepatocellular carcinoma (HCC) is one of the major health problems worldwide.\cite{1,2} It affects more than half a million people worldwide every year, with about a 30% 5-year survival rate.\cite{3,4} Although a variety of therapies have been used to treat HCC in the past few decades, the treatment effect is still unsatisfactory due to postoperative recurrence and drug resistance. Increasing evidence has shown that the molecular pathogenesis of HCC may be closely associated with living environment and genetic factors, such as P53 inactivation, several...
oncogene activation, and gene mutation.\textsuperscript{[5,6]} However, the precise mechanisms underlying HCC development and progression remain unclear.

Recently, the rapid development of high-throughput RNA microarray analysis has allowed us to better understand the underlying mechanisms and general genetic alterations involved in HCC occurrence and metastasis. RNA microarrays have been extensively applied to explore HCC carcinogenesis through gene expression profiles and the identification of altered genes.\textsuperscript{[7–9]} Meanwhile, many large public databases such as The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO) can be performed to screen the differentially expressed genes (DEGs) related to the initiation and progression of HCC from microarray data.

Most HCC patients have a relatively long latent period, therefore many HCC patients are in the intermediate or advanced stage when first diagnosed, in which case radical surgery is no longer desirable.\textsuperscript{[10]} However, many chemotherapies are often with unsatisfactory curative effects and some severe side effects. For example, sorafenib shows a 3-month median survival benefit but is related to 2 grade 3 drug-related adverse events namely diarrhea and hand-foot skin reaction.\textsuperscript{[11]} At present, the disease-free survival (DFS) and overall survival (OS) of HCC patients remained relatively short, highlighting the importance of developing new drugs.

In the study, 3 mRNA expression profiles were downloaded (GSE121249,\textsuperscript{[12]} GSE64041,\textsuperscript{[13]} and GSE62232\textsuperscript{[14]} from the GEO database to identify the genes correlated to HCC progression and prognosis. Integrated analysis included identifying DEGs using the GEO2R tool, overlapping 3 datasets using a Venn diagram tool, GO terms analysis, KEGG biological pathway enrichment analysis, protein–protein interaction (PPI) network construction, hub genes identification and verification, construction of hub genes interaction network, survival analysis of these screened hub genes, and exploration of candidate small molecular drugs for HCC.

### 2. Materials and methods

#### 2.1. Data collection

HCC and adjacent normal tissue gene expression profiles of GSE121248, GSE64041, and GSE62232 were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo/).\textsuperscript{[15]} The microarray data of GSE121248 was based on GPL571 Platforms (Affymetrix Human Genome U133 Plus 2.0 Array) and included 70 HCC tissues and 37 normal tissues (Submission date: October 15, 2018). The GSE64041 data was based on GPL6244 Platforms (Affymetrix Human Gene 1.0 ST Array) and included 60 biopsy pairs from HCC patients, 5 normal liver biopsies (Submission date: December 10, 2014). The data of GSE62232 was based on GPL571 Platforms (Affymetrix Human Genome U133 Plus 2.0 Array) and included 81 HCC cancer tissues and 10 normal liver tissues (Submission date: October 9, 2014). The above datasets meet the following criteria: they used tissue samples from human HCC tissues and adjacent or non-tumor liver tissues; each dataset involved more than 90 samples.

#### 2.2. DEGs identification

GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/) was used to screen the DEGs in HCC tumor tissues and non-tumor liver tissues.\textsuperscript{[16]} Adjusted $P$ values (adj. $P$) $< .05$ and $\mid \log FC \mid > 1$ were set as the cutoff criterion to select DEGs for every dataset microarray, respectively.\textsuperscript{[17]} Then, the overlapping DEGs among these 3 datasets were identified by the Venn diagram tool (https://bioin fop.cnb.csic.es/tools/venny/). Visual hierarchical cluster analysis was also performed to display the volcano plot of DEGs.

#### 2.3. GO and KEGG pathway enrichment analysis

To explore the functions of these DEGs, the DAVID database (https://david.ncifcrf.gov/) was used to perform GO term analysis at first.\textsuperscript{[18]} Then we submitted these DEGs, including 54 upregulated genes and 143 downregulated genes, into the Enrichr database to perform KEGG pathway enrichment analysis. GO term consisted of the following 3 parts: biological process, cellular component, and molecular function. Adj. $P < .05$ was regarded as statistically significant.

#### 2.4. Construction of PPI network and screening of hub genes

PPI network is the network of protein complexes due to their biochemical or electrostatic forces. The Search Tool for the Retrieval of Interacting Genes (STRING) (https://string-db.org/cgi/input.pl/) is a database constructed for analyzing the functional proteins association network.\textsuperscript{[19]} The screened DEGs had been submitted to the STRING database, and all PPI pairs with a combined score of $> 0.4$ were extracted. The degree of all nodes was calculated by Cytoscape (v3.6.1) plugin cyto-Hubba.\textsuperscript{[20]} In the study, these genes with the top 10 highest degree values were regarded as hub genes.

#### 2.5. Validation of hub genes

To validate the mRNA expression level of the hub genes in HCC, the Gene Expression Profiling Interactive Analysis (GEPIA) database was used to show the difference in the mRNA expression level of each hub gene between the liver hepatocellular carcinoma (LIHC) and non-cancerous liver samples.\textsuperscript{[21]} Afterward, the protein expression levels of the hub genes in normal and HCC tissues were visualized through The Human Protein Atlas (HPA) database that contains immunohistochemistry-based expression data for about 20 common types of cancers.\textsuperscript{[22]}

#### 2.6. Genetic alterations of hub genes

The LIHC dataset (TCGA, PanCancer Atlas) including the data of 348 samples was selected to analyze the genetic alterations of hub genes using the cBioPortal database. This database allows for visualization, analysis, and downloading a lot of cancer genomic datasets.\textsuperscript{[23]} These genomic alterations included gene mutations, copy number variations, deep deletion, mRNA expression z-scores (RNA Seq V2 RSEM) with a z-score threshold of ±2.0, and protein expression z-scores. According to the online instructions of cBioPortal, the analysis on DFS and OS was also carried out.

#### 2.7. Survival analysis for hub genes

Kaplan–Meier plotter is extensively applied to explore the roles of more than 54,000 genes in OS based on 13,316 tumor samples from GEO, the European Genome-phenome Archive, and TCGA.
datasets including 364 patients with liver cancer. The relation between OS and hub genes expressed in patients with liver cancer was determined by the Kaplan–Meier survival analysis.\(^{[24]}\) Moreover, the relation between DFS and these genes expressed in LIHC patients was explored through the online tool GEPIA database. The lower and upper 50% of gene expression were set as the standard for analysis. In the present study, HCC patients were divided into 2 groups based on the median expression values of the hub genes. Log-rank \(P<.01\) was regarded as statistically significant.

### 2.8. Drug-hub gene interaction

The screened hub genes were also regarded as promising targets for searching drugs through the DGIdb database (http://dgidb. genome.wustl.edu/).\(^{[123]}\) This database has drug–gene interaction data from 30 disparate sources such as ChEMBL, DrugBank, Ensembl, NCBI Entrez, PharmGKB, and literature in NCBI PubMed. Drugs supported by no less than 2 databases or PubMed references were validated as the candidate drugs. The final list only contained the drugs that have been approved by the Food and Drug Administration. Additionally, the identified target gene network was constructed through the STITCH database (http://stitch.embl.de/), a software that also incorporated drug–gene relationships.\(^{[26,27]}\)

### 3. Results

#### 3.1. Identification of DEGs

According to GSE121248 dataset analysis, 943 DEGs were successfully identified, including 325 upregulated and 618 downregulated genes. For GSE64041 dataset, 289 DEGs were observed, including 87 upregulated and 202 downregulated genes. For GSE62232 dataset, 1355 DEGs were identified, involving 817 upregulated and 538 downregulated genes. Venn analysis was performed to examine the intersection among the 3 DEG profiles. Then, 197 DEGs were identified from the 3 profile datasets (Table 1). Obviously, 54 DEGs were significantly upregulated (Fig. 1A), while 143 DEGs were markedly downregulated (Fig. 1B) in HCC tissues. These 197 DEGs were plotted in Fig. 1C, where the red and green dots represented the upregulated and downregulated DEGs, respectively. In addition, the mRNA expression level of these 197 DEGs was visualized in the form of a heatmap using data profile GSE64041 (Fig. 1D).

#### 3.2. Functional enrichment analysis of DEGs

GO annotation and KEGG pathways enrichment analysis were conducted through the DAVID database and Enrichr database, respectively. The top 10 enriched GO term and KEGG pathways were showed in Table 2. As shown in Table 2, GO biological process analysis revealed that these 197 DEGs were significantly enriched in the oxidation-reduction process, organic acid metabolic process, carboxylic acid metabolic process, and oxoacid metabolic process. The top 4 significantly enriched cellular components terms included extracellular space, extracellular region part, extracellular region, and pronucleus. For GO molecular function analysis, the top 4 significantly enriched terms were monoxygenase activity, oxidoreductase activity, heme binding, and iron ion binding. Additionally, the top 4 markedly enriched pathways for these 197 DEGs were metabolic pathways, tryptophan metabolism, chemical carcinogenesis, and caffeine metabolism.

#### 3.3. PPI network construction and hub genes identification

The STRING database was performed to determine the PPI network among the 197 DEGs. The PPI network including 197 nodes (genes) and 968 edges (interactions) was constructed through the STRING database (see Fig. S1, Supplemental Digital Content, http://links.lww.com/MD2/A456, which shows the PPI network constructed). The PPI enrichment \(P\) value \(<1.0 \times 10^{-16}\). Ten genes with the highest degree scores were regarded as the hub genes by applying the CytoHubba (v3.6.1) plugin cytoHubba. The results revealed that forkhead box M1 (FOXM1) was the hub gene with the highest connectivity degree, followed by aurora kinase A (AURKA), cyclin A2 (CCNA2), cyclin-dependent kinase inhibitor 3 (CKCN3), marker of proliferation Ki-67 (MKI67), enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), cell division cycle 6 (CDC6), cyclin-dependent kinase 1 (CDK1), cyclin B1 (CCNB1), Topoisomerase (DNA) II alpha (TOP2A) (Table 3).

Using cytoHubba software, the PPI network of the screened 10 hub genes was constructed, which had a strong interaction among each other (Fig. 2A). The interaction network of 10 hub genes is illustrated in Fig. 2A. The interaction network of 10 hub genes is illustrated in Fig. 2A. The network includes 9 nodes and 19 edges, where the hub genes (FOXM1, AURKA, CCNA2, MKI67, EZH2, CDC6, CDK1, CCNB1, TOP2A) are highlighted.

| DEGs          | Gene symbol                                                                 |
|---------------|-----------------------------------------------------------------------------|
| Upregulated   | SPINK1, TPX2, EDIL3, ASPM, FVLCR1, AKR1B10, GINS1, SRF01, KPN2A, ANLN, NQ01, FOXM1, EZH2, CCNB2, RBM24, PRC1, CDK1, TOP2A, TXNDR1, SPARQL1, CD06, FAM72A, MAP2, AURKA, BUB1B, DLGAP5, NMRLAP1, LEP1, MKM7, CAP2, DTL, GPC3, CCL20, ROBO1, SPP1, SQLE, KIF20A, UBQ, RRAQD, C2020, ITGA6, LCN2, MELK, SLC7A11, ITGA2, CCNA2, OGN33, BUB1, NU2F, NACAP, UBE2T, CENPF, NUSAP1, ECT2 |
| Downregulated | TUBE1, BBOX1, XDH, SDS, CXXL14, IG1F, DPT, CYP39A1, SLC26A47, PRO2, CBA, ZG16, MBL2, SLC10A1, SLC10A3, PRG4, CYP1A2, UROC1, FGR28, F8, B2DC, AGSM3, CYP2C19, C3P1, LPA, CDS1, GHR, CLEC1B, TAT, LIRF, BHMT, COLEC10, VNN1, LV1E1, STEAP3, SHBG, DNAS1L3, ALDH6A1, NAT2, C7, BOCHE, SAA2-SAA4, AKR1D1, CXXL2, GMST, C1orf168, GR1, CRHPB, CRH3, WDR72, IDO2, BDH2, CYP3A4, SLC38A4, DBH, FBPI, ADH1, ADH2, MT1M, SLC38A5, CEPD, SRD5A2, ADR1A, PBLD, SRPX, CYP4A22, KLKB1, GNAO1, ENOS, MT10, SLC19A3, PGEPY2, TEMN1, NS1-NS2, CYP208, STEAP4, IL13RA2, SPP2, IGHA, MT1F, FEBU, MSFO2A, HHP, APOA5, CYP2E1, KND3, PPP1R38B, LASY, ITGA4, OLFML3, CNR1, FOSN, GADD3, PDGFRA, CLEC4G, PDGFB, CYP2B6, CEP11, FXD1, FXO1, KMO, ANK3, CLRN3, MTH1, HCLEM, NPY1R, ESRI, T002, VIPM1, IGFBP3, PLCL6, HAMP, DCCN, IL1RAP, RDH16, CYP8B1, TMEM77, AFM, HP6D, LPAL2, THBSP, CYP4A11, STAB2, HGFAC, ADGRG7, GPDHL1, FZP2, SLC34C1, REM2, BMPER, AADAT, GPM6A, HGF, MOGAT2, CYP3A4, EPHX2, GLS2, HABP2, APOF, ANGPT1L1, PTGS, GRAM1D1C, SLC7A2 |
genes and their related genes was also identified by the FunRich software (Fig. 2B). The hub genes and their related genes could be enriched in many biological pathways through the enrichment functions of the FunRich tool. KEGG analysis established that markedly enriched pathways for the hub genes included progesterone mediated oocyte maturation, cell cycle, cellular senescence, oocyte meiosis, p53 signaling pathway, viral carcinogenesis, lysine degradation, and gap junction (Fig. 2C).

3.4. Validation of hub genes in HCC

First, a differential analysis on the mRNA expression levels of FOXM1, AURKA, CCNA2, CCKN3, MKI67, EZH2, CDK1, CCNB1, and TOP2A, between HCC and non-tumor liver tissues was conducted through the GEPIA database. As shown in Figure 3, the mRNA expression levels of (Fig. 3A) FOXM1, (Fig. 3B) AURKA, (Fig. 3C) CCNA2, (Fig. 3D) CCKN3, (Fig. 3E) MKI67, (Fig. 3F) EZH2, (Fig. 3G) CDC6, (Fig. 3H) CDK1, (Fig. 3I) CCNB1, and (Fig. 3J) TOP2A were significantly upregulated in HCC tissues ($P < .01$) compared to those in normal liver tissues. These findings were consistent with the obtained GEO microarray data.

Moreover, the protein expression levels of these hub genes in HCC were validated through the HPA database. Obviously, the protein expression levels of FOXM1, AURKA, CCNA2, MKI67, EZH2, CDC6, CDK1, CCNB1, and TOP2A were not observed in HCC tissues compared to normal liver tissues.
or low in normal liver tissues, but medium or high expression levels of these hub genes were detected in HCC tissues (see Fig. S2, Supplemental Digital Content, http://links.lww.com/MD2/A457, which demonstrates protein expression levels of these hub genes in HCC). Unfortunately, the protein expression levels of CDKN3 were not explored because of pending cancer tissue analysis in the HPA database. In brief, these present results showed that mRNA and protein expression levels of these hub genes were overexpressed in HCC tissues.

### 3.5. Survival analysis of the hub genes in HCC

To further explore the relationship between the 10 hub genes and HCC, OS, and DFS analysis of the 10 hub genes were performed by Kaplan–Meier plotter, and the GEPIA database. As showed in Figure 4, high expression levels of FOXM1, AURKA, CCNA2, CDKN3, MKI67, EZH2, CDC6, CDK1, CCNB1, and TOP2A in LIHC patients were related to poor OS. The unfavorable DFS was also significantly shown in LIHC patients with high expression levels of the 10 hub genes (see Fig. S3, Supplemental
Digital Content, http://links.lww.com/MD2/A458, which illustrates DFS of LIHC patients overexpressed the 10 hub genes).

### 3.6. Drug-hub gene interaction

Using the DGIdb database to explore drug-gene interactions of the 10 hub genes, 29 drugs for possibly treating HCC were matched and determined (Table 4). Promising targeted genes of these drugs include AURKB, EZH2, and TOP2A. The final list only included these drugs which were approved by Food and Drug Administration, and several drugs have been tested in clinical trials. Paclitaxel was considered a potential drug for cancer therapy due to its inhibition of AURKA and TOP2A. Etoposide, an inhibitor of TOP2A, could inhibit the development of cancer by inducing DNA damage. Using the STITCH database, we constructed downstream networks of AURKA, EZH2, and TOP2A to investigate the additional effects caused by inhibitors of these genes. Our models showed that AURKA inhibition might have a possible influence on TPX2, microtubule nucleation factor (TPX2), cell division cycle 20 (CDC20), tumor protein p53 (TP53), cell division cycle 25B (CDC25B), baculoviral IAP repeat-containing 5 (BIRC5); EZH2 inhibition might have possible influence on histone deacetylase 1 (HDAC1), BMI1 proto-oncogene, polycomb ring finger (BMI1), YY1 transcription factor (YY1), DNA methyltransferase 3 alpha (DNMT3A), DNA methyltransferase 3 beta (DNMT3B), DNA

---

**Figure 2.** Interaction network and KEGG analysis of the hub genes. (A) The top 10 hub genes in the PPI network were screened by Cytoscape (v3.6.1) plugin cytoHubba. The 10 hub genes are displayed from red (high degree value) to yellow (low degree value). (B) The PPI network of the 10 hub genes and their related genes, created by the FunRich software. (C) KEGG pathway enrichment analysis of the 10 hub genes. KEGG = Kyoto encyclopedia of genes and genomes, PPI = protein–protein interaction, STRING = search tool for the retrieval of interacting genes.
methyltransferase 1 (DNMT1), RB binding protein 4 (RBBP4), embryonic ectoderm development (EED); TOP2A inhibition might have a possible influence on DNA topoisomerase I (TOP1), DNA topoisomerase II beta (TOP2B), ubiquitin C (UBC), proliferating cell nuclear antigen (PCNA), small ubiquitin-like modifier 1 (SUMO1), and SUMO2 (see Figs. S4–S6, Supplemental Digital Content, http://links.lww.com/MD2/A459, http://links.lww.com/MD2/A460, http://links.lww.com/MD2/A461, which shows downstream networks of AURKA, EZH2, and TOP2A respectively). So far, few inhibitors of AURKA, EZH2, and TOP2A have been tested for HCC therapy. Some of these drugs were even not regarded as anti-cancer drugs (such as levofoxacin and dexrazoxane). These data could provide new insights for targeted therapy in HCC patients.

4. Discussion

In the present study, bioinformatics analysis was performed to identify the potential key genes and biological pathways in HCC. Through comparing the 3 DEGs profiles of HCC obtained from the GEO database, 54 upregulated DEGs and 143 downregulated DEGs were identified respectively (Fig. 1). Based on the degree of connectivity in the PPI network, the 10 hub genes were screened and ranked, including FOXM1, AURKA, CCNA2, CDKN3, MKI67, EZH2, CDC6, CDK1, CCNB1, and TOP2A. These 10 hub genes were functioned as a group and may play a key role in the incidence and prognosis of HCC (Fig. 2A). HCC cases with high expression of the hub genes exhibited significantly worse OS and DFS compared to those with low expression of the hub genes (Fig. 4, Fig. S3, http://links.lww.com/MD2/A458). Additionally, 29 identified drugs provided new insights into targeted therapies of HCC (Table 4).

Retinol metabolism, arachidonic acid metabolism, tryptophan metabolism, and caffeine metabolism were most markedly enriched for HCC through KEGG pathway enrichment analysis for 197 DGEs. Metabolic alterations clearly characterize HCC tumors.[29,30] Currently, the rapid development of metabolomics that allows metabolite analysis in biological fluids is very useful for discovering new biomarkers. Lots of new metabolites have been identified by metabolomics approaches, and some of them could be used as biomarkers in HCC.[31]

According to the degree of connectivity, the top 10 genes in the PPI network were regarded as hub genes and they were validated in the GEPIA database, UCSC Xena browser, and HPA database. Many studies reveal that the fork-head box transcription factor FOXM1 is essential for HCC development.[32–34] Over-expression of FOXM1 has been exhibited to be strong relative to poor prognosis and progression of HCC.[35,36] Hepatic progenitor cells of HCC have been identified in the chemical carcinogenesis model, they express cell surface markers CD44 and EpCAM.[32,37] Interestingly, deletion of FOXM1 causes the disappearance of those cells in the tumor nodules, showing that
Figure 4. OS of the 10 hub genes overexpressed in patients with liver cancer was analyzed by Kaplan–Meier plotter. FOXM1, log-rank $P = 0.00036$; AURKA, log-rank $P = 0.0011$; CCNA2, log-rank $P = 0.00018$; CDKN3, log-rank $P = 0.0066$; MKI67, log-rank $P = 0.00011$; EZH2, log-rank $P = 6.8 \times 10^{-6}$; CDC6, log-rank $P = 3.6 \times 10^{-6}$; CDK1, log-rank $P = 1.1 \times 10^{-5}$; CCNB1, log-rank $P = 3.4 \times 10^{-5}$; and TOP2A, log-rank $P = 0.00012$. Data are presented as Log-rank $P$ and the hazard ratio with a 95% confidence interval. Log-rank $P < 0.01$ was regarded as statistically significant. OS = overall survival.
FOXM1 is critical for the CD44 and EpCAM positive HCC cells.[32] The hepatic cancer stem cells in human HCC lines also depend on FOXM1, because deletion of FOXM1 will lead to loss of these cancer stem cells.[32] FOXM1 is a critical downstream factor of many cancer signaling pathways, such as Wnt/β-catenin signaling.[38] Moreover, FOXM1 stimulates the expression of some multifunctional genes, like c-Myc, Oct4, Sox2, and Nanog.[39,40]

AURKA is a mitotic serine/threonine kinase that regulates cell mitosis, cell division, and cell cycle progression.[41] AURKA overexpression has been observed in HCC.[42] And AURKA overexpression has been closely related to the aggressive tumor characteristics,[43] poor prognosis,[44] and drug resistance[45] of HCC. AURKA was regulated by c-Myc which contributes to cancer progression in HCC.[46] Alisertib, an inhibitor of AURKA, could inhibit cell viability and induce apoptosis in HCC cells.[47] Wang et al showed genetic variations of AURKA may be a reliable biomarker for the development of HCC.[48] Our study also indicated that increased expression levels of AURKA were related to the unfavorable OS and DFS in HCC patients.

CCNA2[49] and CCNB1[50] are 2 members of the cyclin family, which regulate cell proliferation and apoptosis, and have been closely related to cancer progress and patients’ survival. CCNA2[51] and CCNB1[52,53] have been identified in various types of tumors. CCNA2 was overexpressed in human HCC tissues.[54] Moreover, it was reported that CCNA2 was relative to a decrease in OS for HCC patients, based on the survival and expression data from TCGA.[55] Liu et al revealed that CCNB1 was highly expressed in HCC tissues compared with normal liver tissues.[56] In addition, the overexpression of CCNB1 was correlated to poor OS and DFS in HCC patients by bioinformatics analysis.[57] Our study also revealed that HCC patients with a high expression level of CCNA2 or CCNA2 exhibited worse OS and DFS compared to those with a low expression level.

CDKN3 gene is involved in cell mitosis by modulating CDK1/CDK2 dephosphorylation, and its overexpression correlates with unfavorable survival in several cancers.[58] For HCC, CDKN3 not only promotes cell proliferation but also correlates with tumor pathological grade negatively.[59] CDK1, a member of the Ser/Thr protein kinase family, plays an essential role in the control of the eukaryotic cell cycle by modulating the centrosome cycle. CDK1 has been extensively investigated in ovarian cancer and colorectal cancer.[60,61] However, little is known about the role of CDK1 in HCC carcinogenesis. A recent study has found that metformin can significantly inhibit the proliferation of HCC cells and effectively reduce the expression of CDK1.[62] In the present study, the high expression of CDK1 is associated with unfavorable OS and DFS in HCC patients.

The maker of proliferation Ki-67 expresses in all phases of the cellular cycle over than G0 phase.[63] MKI67 protein expression in carcinomas has been intensively investigated, and the MKI67-positive cell rate has been shown to be associated with clinical-
pathological features and even clinical outcomes in various cancers, including HCC. In a study of patients undergoing surgical resection for HCC, higher levels of MKI67 expression in tumor tissue were associated with a higher tumor grade and early tumor recurrence. Furthermore, staining for MKI67 and P53 are widely used to predict the clinical outcomes of HCC patients after resection and liver transplantation.

EZH2 is a member of the polycomb group (PcG) protein family, which modifies transcription at the epigenetic level by regulating histone and DNA methylation. Lots of studies have shown that many tumor suppressor genes are suppressed by EZH2 in malignancies and that EZH2 dysregulation plays a crucial role in carcinogenesis. In our study, the expression of EZH2 was higher in HCC tumor tissue, and the high expression of EZH2 was associated with unfavorable OS and DFS in HCC patients.

CDC6 plays a critical role in the initiation of DNA replication. As cells enter the G1 phase, CDC6 binds to the origin recognition complex and initiates the assembly of the pre-replicative complex (pre-RC) with chromatin licenses and DNA replication factor 1 and mini-chromosome maintenance proteins. Once phosphorylated by CDKs at the G1/S phase, CDC6 is released from the pre-RC and then DNA is licensed for replication. Growing evidence has suggested that deregulation of CDC6 may contribute to cancer initiation and progression. Overexpression of the CDC6 protein has been observed in different types of cancer. Our study reveal that the expression of CDC6 was higher in HCC tumor tissue and the high expression of CDC6 was related to unfavorable OS and DFS in HCC patients.

TOP2A, is a key nuclease that facilitates the temporary cleavage and ligation cycle of DNA. In all forms of topoisomerases, TOP2A is predominantly involved in proliferating cells and overexpressed in a variety of cancers (such as breast cancer, urinary bladder cancer, and ovarian carcinoma). For HCC, bioinformatics analysis showed that overexpression of TOP2A was common in HCC tumor tissues relative to those in normal liver tissues. Moreover, Wong et al found that the high expression of TOP2A was correlated with microvascular invasion, advanced histological grading, chemotherapy resistance, and poor survival rate. In our study, the expression of TOP2A was higher in HCC tumor tissue compared to normal liver tissue, and associated with unfavorable OS and DFS in HCC patients.

A list of 29 drugs with potential therapeutic efficacy against HCC was identified through the DGIdb database. Among the 10 hub genes, the potential gene targeting the drugs are AURKB, EZH2, and TOP2A. In Table 3, most of the drugs were inhibitors of AURKB, EZH2, and TOP2A. Some researchers also have identified similar molecules, such as phenoxybenzamine, emetine, fendiline, which may be effective drugs against HCC. Nevertheless, the present study might push new valuable insights into the individualized and targeted therapy for HCC, and the identified conventional drugs were of potential new use.

5. Conclusions
In summary, the study identified commonly changed 197 DEGs in HCC through using integrated bioinformatics analysis, including 54 upregulated DEGs and 143 downregulated DEGs. And 10 hub genes (FOXM1, AURKA, CCNA2, CDKN3, MKI67, EZH2, CDC6, CDK1, CCNB1, and TOP2A) might play important roles in HCC. The expression of the hub genes was revealed to be increased in HCC, and the overexpression level predicted a poor prognosis. The 10 hub genes might function as novel markers and/or targets for the early HCC detection, prognostic judgment, and targeted therapy of HCC. Additionally, a number of drugs targeting the hub genes were identified, and they could be potentially utilized for the treatment of HCC patients. This study provided a powerful basis for HCC studies, and further experimental studies were needed.

Acknowledgments
We sincerely thank the GEO, Enrichr, STRING, GEPIA, TCGA, HAP, cBioPortal, Kaplan–Meier plotter, DGIdb, and STITCH databases for providing their platforms and contributors for their valuable data.

Author contributions
Concept and design: Ping Huang; analysis and interpretation of the data: Xiaolong Chen; acquisition of data: Xiaolong Chen and Zhixiong Xia; making diagrams and tables of the article: Xiaolong Chen and Yafeng Wan; drafting of the article: Xiaolong Chen and Zhixiong Xia; critical revision and final approval of the article: Ping Huang.

Conceptualization: Ping Huang.
Data curation: Xiaolong Chen.
Formal analysis: Xiaolong Chen.
Funding acquisition: Ping Huang.
Investigation: Xiaolong Chen.
Methodology: Xiaolong Chen, Yafeng Wan.
Resources: Zhixiong Xia.
Software: Zhixiong Xia.
Supervision: Ping Huang.
Validation: Ping Huang.
Visualization: Xiaolong Chen, Zhixiong Xia, Yafeng Wan.
Writing – original draft: Xiaolong Chen.
Writing – review & editing: Ping Huang.

References
[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
[2] Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
[3] Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093–107.
[4] Si T, Chen Y, Ma D, et al. Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol 2017;32:1286–94.
[5] An P, Xu J, Yu Y, Winkler CA. Host and viral genetic variation in HBV-related hepatocellular carcinoma. Front Genet 2018;9:261.
[6] Tang R, Liu H, Yuan Y, et al. Genetic factors associated with risk of metabolic syndrome and hepatocellular carcinoma. Oncotarget 2017;8:35403–11.
[7] Chen CF, Hsu EC, Lin KT, et al. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology 2010;52:1690–701.
[8] Miek M, Chmelarová M, John S, et al. Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma. Clin Chem Laborat Med 2016;54:1971–80.
[9] Zhen L, Shijie N, Shuijun Z. Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection. Medicine 2014;93:e179.
[10] Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144–58.
[11] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
[12] Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Cancer Res 2007;67:2675–83.
[13] Makowska Z, Boldanova T, Adametz D, et al. Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res 2016;2:80–92.
[14] Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of liver transplant patients. Nat Genet 2015;47:505–11.
[15] Barrett T, Willhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013;41:D991–5.
[16] Guo Y, Bao Y, Ma M, Yang W. Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int J Mol Sci 2017;18:722.
[17] Lebrec J, Huizinga TW, Toes RE, Houwing-Duistermaat JJ, van Houwelingen HC. Integration of gene ontology pathways with North American Rheumatoid Arthritis Consortium genome-wide association data via linear modeling. BMC Proc 2009;3:S94.
[18] Wu M, Liu Z, Zhang A, Li N. Identification of key genes and pathways in hepatocellular carcinoma: a preliminary bioinformatic analysis. Medi-Medi (Bamnien) 2019;98:14287.
[19] Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made widely accessible. Nucleic Acids Res 2017;45:D362–8.
[20] Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 2014;8:S11.
[21] Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for identifying hub objects and sub-networks from complex interactome.
[22] Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.
[23] Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006.
[24] Cotto KC, Wagner AH, Feng YY, et al. DGDhib 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res 2018;46:D1068–73.
[25] Kirk J, Shah N, Noll B, et al. Text mining-based in silico drug discovery in oral mucositis caused by high-dose chemotherapy. Support Care Cancer 2018;26:2695–705.
[26] Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res 2016;44:D380–4.
[27] Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access platform for exploring multidimensional cancer genomics data.
[28] Volm M, Koomagi R, Mattern J, Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinoma. Br J Cancer 1997;75:1747–8.
[29] Ding K, Li W, Zou Z, Zou X, Wang C. CCNB1 is a prognostic biomarker for ER+ breast cancer. Med Hypotheses 2014;83:339–44.
[30] Kitamura K, Yamazaki M, Takehara H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal cancer: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1990;48:225–33.
[31] Wang A, Yoshihito N, Nito T, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol 1997;123:124–7.
[32] Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60:4000–3.
[33] Christiansen OM, Studach L, Merle P. Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 2011;21:4–9.
[34] Qi XJ, Yi Y, Li W, Shi L, Huang T, Wu P. Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus-positive cirrhosis. Mol Med Rep 2018;18:4940–50.
[35] Liu S, Yao X, Zhang D, et al. Analysis of transcription factor-related regulatory networks based on bioinformatics analysis and validation in hepatocellular carcinoma. Biomed Res Int 2018;2018:1431396.
[36] Gao X, Wang X, Zhang S. Bioinformatics identification of crucial genes and pathways associated with hepatocellular carcinoma. Biosci Rep 2018;38:BSR20181441.
[37] Chiu W, Yu P, Wu J. Expression and alternative splicing of the cyclin-dependent kinase inhibitor p21 in human cancer. Int J Biochem Cell Biol 2017;91:98–101.
[38] Wang C, Chen G, Wang J, et al. Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. Oncotarget 2016;7:49481–97.
Zhang R, Shi H, Ren F, et al. The aberrant upstream pathway regulations of CDK1 protein were implicated in the proliferation and apoptosis of ovarian cancer cells. J Ovarian Res 2017;10:60.

Zhou J, Han S, Qian W, Gu Y, Li X, Yang K. Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. OncoTargets Ther 2018;11:4451–9.

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–5.

Luo Y, Ren F, Liu Y, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med 2105;8:10235–47.

D’Errico A, Grigioni WF, Fiorentino M, Baccarini P, Grazi GL, Mancini AM. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol Int 1994;44:682–7.

Guzman G, Alagiozian-Angelova V, Layden-Almer JE, et al. p53, Ki-67, and serum alpha fetoprotein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005;18:1498–503.

Gao SB, Zheng QF, Xu B, et al. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma. Mol Cancer Res 2014;12:1388–97.

Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741–50.

Xu B, Konze KD, Jin J, Wang GG. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol 2015;43:698–712.

Chen et al. Medicine (2021) 100:39

[70] Au SL, Wong CC, Lee JM, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012;56:622–31.

[71] Randell JC, Bowers JL, Rodriguez HK, Bell SP. Sequential ATP hydrolysis by Cdc6 and ORC directs loading of the Mcm2-7 helicase. Mol Cell 2006;21:29–39.

[72] Speck C, Stillman B. Cdc6 ATPase activity regulates ORC-Cdc6 stability and the selection of specific DNA sequences as origins of DNA replication. J Biol Chem 2007;282:11705–14.

[73] Borlado LR, Méndez J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 2008;29:237–43.

[74] Semple JW, Duncker BP. ORC-associated replication factors as biomarkers for cancer. Biotechnol Adv 2004;22:621–31.

[75] Ali Y, Abd Hamid S. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy. Tumour Biol 2016;37:47–55.

[76] Zhou L, Du Y, Kong L, Zhang X, Chen Q. Identification of molecular target genes and key pathways in hepatocellular carcinoma by bioinformatics analysis. Oncol Targets Ther 2018;11:1861–9.

[77] Wong N, Yeo W, Wong WL, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009;124:644–52.

[78] Fang E, Zhang X, Wang Q, Wang D. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach. Cancer Biomark 2017;20:533–61.

[79] Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015;9:4479–99.

[80] Sho T, Nakanishi M, Morikawa K, et al. A phase I Study of combination therapy with sorafenib and 5-fluorouracil in patients with advanced hepatocellular carcinoma. Drugs R D 2017;17:381–8.